F
Fulford
FULFORD
Fulford
Healthcare Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 220%
Weaknesses
3- Stock is trading at 8.03 times its book value
- The company has delivered a poor sales growth of -14.7% over past five years.
- Company has a low return on equity of 13.1% over last 3 years.
Growth Rate
Revenue Growth
-36% lower than
3Y
Net Income Growth
-36% lower than
3Y
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 46.65 | 61.48 | 59.69 | 55.83 | 45.99 | 57.07 | 64.39 | 49.14 | 46.47 |
| Expenses | 54.78 | 60.05 | 54.91 | 53.42 | 51.12 | 55.72 | 56.84 | 60.33 | 52.82 |
| Operating Profit | -8.13 | 1.43 | 4.78 | 2.41 | -5.13 | 1.35 | 7.55 | -11.19 | -6.35 |
| OPM % | -17.43% | 2.33% | 8.01% | 4.32% | -11.15% | 2.37% | 11.73% | -22.77% | -13.66% |
| Other Income | 2.58 | 2.45 | 2.25 | 2.68 | 2.58 | 2.29 | 2.88 | 2.17 | 6.88 |
| Interest | 0.01 | 0.77 | 0 | 0.04 | 0.13 | 0.01 | 0.01 | 0.24 | -0.07 |
| Depreciation | 0.39 | 0.33 | 0.28 | 0.27 | 0.25 | 0.21 | 0.22 | 0.12 | 0.05 |
| PBT | -5.95 | 2.78 | 6.75 | 4.78 | -2.93 | 3.42 | 10.2 | -9.38 | 0.55 |
| Tax % | -31.93% | 33.81% | 35.26% | 27.2% | -60.07% | 33.92% | 34.22% | -31.34% | 140% |
| Net Profit | -4.05 | 1.84 | 4.37 | 3.48 | -1.17 | 2.26 | 6.71 | -6.44 | -0.22 |
| EPS in Rs | -10.38 | 4.72 | 11.21 | 8.92 | -3 | 5.79 | 17.21 | -16.51 | -0.56 |
Profit & Loss
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 190 | 213 | 213 | 265 | 230 | 155 | 142 | 122 | 100 | 109 | 70 |
| Expenses | 167 | 179 | 218 | 228 | 270 | 239 | 182 | 119 | 99 | 79 | 79 | 44 |
| Operating Profit | 17 | 11 | -5 | -15 | -5 | -9 | -27 | 23 | 22 | 21 | 30 | 26 |
| OPM % | 9% | 6% | -2.3% | -7% | -1.8% | -3.8% | -17% | 16% | 18% | 21% | 28% | 38% |
| Other Income | 6 | 8 | 9 | 10 | 13 | 14 | 6 | 7 | 7 | 19 | 9 | 5 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 22 | 17 | 3 | -7 | 5 | 5 | -21 | 29 | 29 | 39 | 39 | 31 |
| Tax % | 39% | 31% | 32% | -31% | 18% | 52% | -33% | 39% | 39% | 30% | 27% | 41% |
| Net Profit | 13 | 12 | 2 | -5 | 4 | 2 | -14 | 18 | 18 | 28 | 28 | 18 |
| EPS in Rs | 34.51 | 30.92 | 4.72 | -12.79 | 11.46 | 5.92 | -36.26 | 45.46 | 45.72 | 71.26 | 72.67 | 46.36 |
| Div. Payout % | 13% | 15% | 74% | -8% | 17% | 25% | 0% | 2% | 2% | 5% | 1% | 654% |
Balance Sheet
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 136 | 146 | 146 | 141 | 144 | 146 | 132 | 150 | 167 | 194 | 222 | 111 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 37 | 42 | 66 | 56 | 59 | 41 | 43 | 52 | 41 | 28 | 29 | 35 |
| Total Liabilities | 177 | 192 | 216 | 201 | 208 | 191 | 179 | 205 | 212 | 227 | 255 | 150 |
| Fixed Assets | 6 | 6 | 4 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 156 | 187 | 212 | 198 | 206 | 190 | 177 | 204 | 211 | 226 | 255 | 150 |
| Total Assets | 177 | 192 | 216 | 201 | 208 | 191 | 179 | 205 | 212 | 227 | 255 | 150 |
Cash Flow
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -5 | 6 | 11 | -27 | 9 | -76 | 6 | 17 | 7 | 7 | 4 | 34 |
| Investing | 1 | 18 | 8 | 8 | 10 | 13 | -31 | 42 | -43 | -3 | 70 | 4 |
| Financing | -1 | -2 | -2 | -2 | -1 | -1 | -1 | 0 | 0 | -1 | -1 | -129 |
| Net Cash Flow | -5 | 22 | 17 | -20 | 18 | -64 | -26 | 58 | -36 | 3 | 73 | -92 |
| Free Cash Flow | -9 | 4 | 11 | -27 | 9 | -76 | 5 | 17 | 8 | 7 | 4 | 34 |
| CFO/OP | 37 | 143 | -329 | 156 | -376 | 764 | -68 | 156 | 97 | 112 | 81 | 163 |
Ratios
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 29 | 22 | 16 | 11 | 4 | 32 | 21 | 26 | 10 | 12 | 59 | 34 |
| Inventory Days | 142 | 125 | 145 | 138 | 97 | 175 | 118 | 167 | 117 | 119 | 21 | 121 |
| Days Payable | 112 | 127 | 160 | 123 | 126 | 68 | 92 | 220 | 217 | 155 | 193 | 222 |
| Cash Conversion Cycle | 59 | 20 | 1 | 26 | -25 | 139 | 47 | -27 | -90 | -25 | -113 | -67 |
| Working Capital Days | 50 | 52 | -2 | 17 | -14 | 75 | 9 | -13 | -20 | 7 | 24 | -32 |
| ROCE % | 17% | 12% | 2% | -5% | 4% | 3% | -15% | 20% | 18% | 22% | 18% | 18% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fulford insights
43 extracted metrics + investor summaries across FY09–FY21.
Documents
1
Updates on Delisting Offer
31 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement is being issued by Dashtag (“Acquirer”) to the equity shareholders of Fulford (India) … 31 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement is being issued by Dashtag (“Acquirer”) to the equity shareholders of Fulford (India) …
2
Updates on Delisting Offer
31 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement is being issued by Dashtag (“Acquirer”) to the equity shareholders of Fulford (India) … 31 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement is being issued by Dashtag (“Acquirer”) to the equity shareholders of Fulford (India) …
3
Shareholding Pattern For June 30, 2015
22 Jul 2015 - Fulford India Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015. 22 Jul 2015 - Fulford India Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015.
4
Shareholding Pattern For June 30, 2015
22 Jul 2015 - Fulford India Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015. 22 Jul 2015 - Fulford India Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015.
5
Updates on Delisting Offer
18 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement (“Post Offer PA”) is being issued by Dashtag (“Acquirer”) to the equity shareholders … 18 Jul 2015 - Fulford India Ltd has submitted to BSE a copy of Public Announcement (“Post Offer PA”) is being issued by Dashtag (“Acquirer”) to the equity shareholders …
Frequently Asked Questions about Fulford
What does Fulford (India) Ltd do?
Fulford (India) is engaged in the business of trading of Pharmaceuticals.
Which sector does Fulford (India) Ltd belong to?
Fulford (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Fulford (India) is engaged in the business of trading of Pharmaceuticals.
Website fulfordindia.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FULFORD.md for Fulford (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.